NewAmsterdam Pharma Company N.V.

NASDAQ•NAMS

CEO: Dr. Michael Harvey Davidson FACC, Facp., M.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-02-09

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

連絡先情報

Gooimeer 2-35, Naarden, 1411 DC, Netherlands

31-35-206-2971

www.newamsterdampharma.com

時価総額

$3.96B

PER (TTM)

-19.3

19.2

配当利回り

52週高値

$42.00

52週安値

$15.70

52週レンジ

71%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

5年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2021-2025

財務ダッシュボード

Q4 2025 データ

売上高

$32.00K+0.00%

直近4四半期の推移

EPS

-$0.65+0.00%

直近4四半期の推移

フリーCF

-$40.98M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Phase 3 Trials Met Endpoints Obicetrapib met primary LDL-C lowering endpoints in BROADWAY and BROOKLYN Phase 3 trials, showing strong efficacy.

Menarini Regulatory Submissions Complete MAAs submitted to EMA/UK/Switzerland for obicetrapib; decisions anticipated in second half of 2026.

Operating Loss Decreased Annual loss for the year narrowed by $37.8M to $203.8M, despite revenue falling 50.6% to $22.5M.

Cash Position Supports Operations Ending cash, equivalents, and restricted cash totaled $491.3M as of December 31, 2025, sufficient for near-term needs.

リスク要因

Clinical Stage and Profitability Risk Company remains clinical-stage, incurred $203.8M loss in 2025, and anticipates continued significant losses indefinitely.

Substantial Financing Required Requires substantial additional capital to achieve goals; failure to secure funding could delay or terminate product development efforts.

Increased Cash Used Investing Cash used in investing activities rose sharply to $174.9M in 2025, contributing to a $280.4M decrease in total cash balance.

Dependence on Obicetrapib Success Future success entirely dependent on successful clinical development, regulatory approval, and commercialization of obicetrapib.

見通し

Complete PREVAIL Cardiovascular Outcomes Continue executing PREVAIL CVOT to evaluate MACE benefit; earliest conclusion expected end of 2026 or later.

Await European Regulatory Decisions Anticipate Menarini receiving regulatory decisions on MAAs from European regulators in the second half of 2026.

Initiate Alzheimer's Disease Trial Expect to initiate a new clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease during 2026.

Pursue US Commercialization Strategy Current plan focuses on pursuing development and commercialization in the United States ourselves, considering additional partners.

同業比較

売上高 (TTM)

ARWR

$1.09B

+4081.8%

LGND

$268.09M

+60.4%

SLNO

$190.41M

+0.0%

粗利益率 (最新四半期)

KYMR

2763.6%

-2680.7pp

LGND

143.6%

+2.6pp

CRNX

111.8%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ARWR	$9.34B	46.2	36.1%	19.5%
KYMR	$7.34B	-24.4	-29.1%	4.7%
PRAX	$7.26B	-25.5	-58.7%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-77.9%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし